PureTech Health (PRTC) Short-term Investments (2019 - 2025)
PureTech Health (PRTC) reported Short-term Investments of $59.3 million for Q2 2025, down 31.57% on a QoQ basis from $86.7 million in Q4 2024.
PureTech Health (PRTC) has 4 years of Short-term Investments data on file, last reported at $59.3 million in Q2 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $59.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $59.3 million (changed N/A YoY) and the FY2024 annual result came in at $86.7 million, changed N/A from the prior year.
- Short-term Investments retreated to $59.3 million in Q2 2025 per PRTC's latest filing, from $86.7 million in the prior quarter.
- Across five years, Short-term Investments topped out at $200.2 million in Q4 2022 and bottomed at $59.3 million in Q2 2025.
- The 3-year median for Short-term Investments is $86.7 million (2024), against an average of $115.4 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 59.30 Mn |
| Dec 31, 2024 | 86.67 Mn |
| Dec 31, 2022 | 200.20 Mn |
| Dec 31, 2019 | 30.09 Mn |